1. Generics Bulletin
  2. >>Business
  3. >>Deals

JB Chemicals Acquires Several Sanzyme Brands

The $83m Transaction Is Expected To Close Within The Next Two Weeks

 
• By Chloe Kent

JB Chemicals has purchased a number of leading brands from Sanzyme, which it plans to scale up and institutionalize within India. The transaction, worth over $80m, is expected to close within the next two weeks.

Close-up of bottles on conveyor belt in factory
JB Chemicals has experienced a conveyor belt of executive changes since its acquisition by KKR • Source: Alamy

JB Chemicals & Pharmaceuticals Ltd. has acquired a number of brands in the probiotics, therapeutic nutraceuticals and reproductive health markets from Sanzyme, in a transaction valued at INR6.28bn ($83.4m). The deal is expected to be completed within the next two weeks following customary closing formalities, having been signed off at a 25 January board meeting.

“Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise,” JB Chemicals said, adding that Sanzyme

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.